Hybrid closed-loop system
Hybrid closed-loop system has been studied in 3 papers since 2026: 1 trial and 1 observational study in people, 1 review; 3 in the past year. The newest paper, Oct 26, 2026: “Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics”.
3 papers study it7 findingsUpdated
1 new paper in 30 daysSee all 3 papers on hybrid closed-loop system
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“patients on Hybrid closed-loop systems showed a 2-fold and a 4-fold higher increase in time in range”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Hellenic Diabetes Association
- 4 of 7 findings with company ties
- Human trial1
- Humans1
Studies in people
1 study gave hybrid closed-loop system to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases time in range2-fold and 4-fold higher increase down: Decreases pulse wave velocity-15.71% vs +5.67% (P < 0.05) down: Decreases central systolic blood pressure-8.15% vs +1.49% (P < 0.05) | Trial12 months | 90 peoplePoorly controlled type 1 diabetes | Diabetes technology & therapeutics, Feb 5, 2026 |
What did studies of hybrid closed-loop system find?
6Studies of hybrid closed-loop system measured 6 outcomes, among them pulse wave velocity, global longitudinal strain and time in normal glucose range.
Pulse wave velocity
downin humans2
2 studies
Pulse wave velocity
downin humans2
Hybrid closed-loop system decreases pulse wave velocity in humans (Poorly controlled type 1 diabetes; compared with intensified multiple daily injections) (-15.71% versus +5.67% with multiple daily injections; P<0.05).
“Hybrid closed-loop systems and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%)”
Human trialPoorly controlled type 1 diabetes; compared with intensified multiple daily injections12 months
ESC Congress 2026 abstract
Hybrid closed-loop system decreases pulse wave velocity in humans (poorly controlled type 1 diabetes) (-15.71% vs +5.67% (P < 0.05)).
“At 12 months, HCLS and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%), cSBP (-8.15% and -6.88%), and PBR (-6.98% and -8.98%) compared with MDI”
Human trialpoorly controlled type 1 diabetes12 months
Diabetes technology & therapeutics
Global longitudinal strain
upin humans1
1 study
Global longitudinal strain
upin humans1
Hybrid closed-loop system improves global longitudinal strain in humans (Poorly controlled type 1 diabetes; compared with intensified multiple daily injections) (6.7% improvement versus 2.2% with multiple daily injections; P<0.05).
“Hybrid closed-loop systems and SGLT-2i group displayed the most significant improvement in GLS (6.7 % and 4 %)”
Human trialPoorly controlled type 1 diabetes; compared with intensified multiple daily injectionsmyocardium12 months
ESC Congress 2026 abstract
Time in normal glucose range
upin humans1
1 study
Time in normal glucose range
upin humans1
Hybrid closed-loop system increases time in normal glucose range in humans (Poorly controlled type 1 diabetes; compared with intensified multiple daily injections) (4-fold higher increase than multiple daily injections; P <0.001).
“patients on Hybrid closed-loop systems showed a 2-fold and a 4-fold higher increase in time in range”
Human trialPoorly controlled type 1 diabetes; compared with intensified multiple daily injections12 months
ESC Congress 2026 abstract
Perfused boundary region
downin humans1
1 study
Perfused boundary region
downin humans1
Hybrid closed-loop system decreases perfused boundary region in humans (poorly controlled type 1 diabetes) (-6.98% vs +1.99% (P < 0.05)).
“At 12 months, HCLS and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%), cSBP (-8.15% and -6.88%), and PBR (-6.98% and -8.98%) compared with MDI”
Human trialpoorly controlled type 1 diabetes12 months
Diabetes technology & therapeutics
Central systolic blood pressure
downin humans1
1 study
Central systolic blood pressure
downin humans1
Hybrid closed-loop system decreases central systolic blood pressure in humans (poorly controlled type 1 diabetes) (-8.15% vs +1.49% (P < 0.05)).
“At 12 months, HCLS and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%), cSBP (-8.15% and -6.88%), and PBR (-6.98% and -8.98%) compared with MDI”
Human trialpoorly controlled type 1 diabetes12 months
Diabetes technology & therapeutics
Time in range
upin humans1
1 study
Time in range
upin humans1
Hybrid closed-loop system increases time in range in humans (poorly controlled type 1 diabetes) (2-fold and 4-fold higher increase).
“patients on HCLS showed a 2-fold and a 4-fold higher increase in TIR compared with SGLT-2i (P = 0.026) and MDI group (P < 0.001), respectively.”
Human trialpoorly controlled type 1 diabetes12 months
Diabetes technology & therapeutics